Artiria Medical Company Research Report

Company Overview

• Name: Artiria Medical

• Mission: Artiria's mission is to help reduce the mortality and morbidity following a stroke through minimally invasive approaches while addressing a strong unmet medical need.

• Founded: 2019

• Founders: Guillaume Petit-Pierre and Marc Boers

• Key People:

• Guillaume Petit-Pierre - CEO and Co-Founder

• Marc Boers - COO and Co-Founder

• Julien Cevey - Quality Manager

• Benoît Dubath - R&D Engineer

• Priya Gaiha - Head of Medical Affairs US

• Francesco Galizzi - Embedded Systems Engineer

• Hadrien Michaud - R&D Manager

• Silvia Scarabelli - Clinical & Regulatory Affairs Manager

• Loïc Sottas - R&D Project Leader

• Headquarters: Switzerland

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: Developing cutting-edge technologies to revolutionize neurointerventional procedures, specifically targeting stroke treatment.

Products

Deflectable Guidewire

• Description: A neurovascular guidewire with a real-time deflectable tip, designed to improve navigation through complex vascular anatomies.

• Key Features:

• Real-time Deflection: Allows shaping of the tip in situ without removal.

• Removable Handle: Facilitates reliable adjustments to the guidewire.

• Intuitive Control: Offers accessible handling and precise navigation through blood vessels.

• Enhanced Access: Facilitates seamless navigation and trackability to distal neurovascular targets thanks to a unique coating.

Recent Developments

• FDA Clearance: Artiria's deflectable guidewire received FDA 510(k) clearance in May 2023, marking a significant advancement in stroke treatment.

• Funding: Secured CHF 3.8 million in April 2022 and USD 6M in February 2024 for clinical studies, including support from various partners like the Wyss Center for Bio and Neuroengineering and Verve Ventures.

• Clinical Studies: Initiated first-in-human clinical studies in 2023 following pilot testing.

• Strategic Partnerships: Collaboration with key opinion leaders in Europe and the US to conduct randomized controlled studies on their products.

• Innovations and Awards: Artiria has won several awards, including the 1st price of Mass Challenge Switzerland (2019), and is supported by multiple innovation and research programs.

New Product Launches

• Real-time Deflectable Guidewire: Entered first-in-human clinical studies in the third quarter of 2023.

New Features

• Innovative Handle and Connection System: Allows dynamic adjustments and re-clamping to the guidewire during procedures, providing agility and control.

• Unique Guidewire Coating: Enhances neurovascular target access and improves patient outcomes.

New Partnerships

• Funding Partners: The latest Series A2 round investments involved 4FOX Ventures, Wyss Center for Bio and Neuroengineering, and existing investors.

• Regulatory and Clinical Support: Collaboration with U.S.-based centers to enhance clinical effectiveness demonstration and facilitate market approvals.

This report is compiled based on the most recent data available, providing an in-depth look at Artiria Medical's status, offerings, and strategic endeavors.